Diabetes mellitus increases the risk of bladder cancer: An updated meta-analysis of observational studies

Diabetes Technology and Therapeutics

Volumn 15, Issue 11, 2013, Pages 914-922

  Fang, Hong ^a   Yao, Baodong ^a   Yan, Yujie ^a   Xu, Huilin ^a   Liu, Yinan ^a   Tang, Hongmei ^a   Zhou, Jie ^a   Cao, Lili ^a   Wang, Weijie ^a   Zhang, Jinling ^a   Zhao, Liyun ^a   Chen, Xi ^a   Zhang, Fen ^a   Zhao, Yanping ^a  

^a Shanghai Minhang District Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

ARTICLE; BLADDER CANCER; BODY MASS; CANCER RISK; COHORT ANALYSIS; DIABETES MELLITUS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; SMOKING; SYSTEMATIC REVIEW;

CASE-CONTROL STUDIES; COHORT STUDIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERGLYCEMIA; INSULIN RESISTANCE; MALE; ODDS RATIO; RISK; SEX FACTORS; URINARY BLADDER NEOPLASMS;

EID: 84887106867     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2013.0131     Document Type: Article

References (58)

1. The IDF Diabetes Atlas, 5th ed. www.idf.org/diabetesatlas/5e/diabetes (accessed February 5, 2013).
2. He J, Stram DO, Kolonel LN, Henderson BE, Le Marchand L, Haiman CA: The association of diabetes with colorectal cancer risk: the Multiethnic Cohort. Br J Cancer 2010;103: 120-126.
3. Attner B, Landin-Olsson M, Lithman T, Noreen D, Olsson H: Cancer among patients with diabetes, obesity and abnormal blood lipids: a population-based register study in Sweden. Cancer Causes Control 2012;23:769-777.
4. Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM: Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005;293:194-202.
5. U.S. Cancer Statistics Working Group: United States Cancer Statistics: 1999-2006 Incidence and Mortality Web-Based Report. Atlanta: Centers for Disease Control and Prevention, Department of Health and Human Services, and National Cancer Institute, 2010.
6. Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC: Association between smoking and risk of bladder cancer among men and women. JAMA 2011;306:737-745.
7. World Cancer Research Fund, American Institute for Cancer Research: Food, Nutrition, Physical Activity and the Prevention of Cancer: A Global Perspective. Washington, DC: American Institute for Cancer Research, 2007.
8. Neumann A, Weill A, Ricordeau P, Faqot JP, Alla F, Allemand H: Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia 2012;55:1953-1962.
9. Larsson SC, Orsini N, Brismar K, Wolk A: Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 2006;49:2819-2823.
10. Tseng CH: Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan. Diabetologia 2011;54:2009-2015.
11. Larsson SC, Andersson SO, Johansson JE, Wolk A: Diabetes mellitus, body size and bladder cancer risk in a prospective study of Swedish men. Eur J Cancer 2008;44:2655-2660.
12. Zhu ZW, Zhang XH, Shen ZJ, Zhong Shan, Wang XJ, Lu YL: Diabetes mellitus and risk of bladder cancer: a meta-Analysis of cohort studies. PLOS One 2013;8:e56662.
13. Hill AB: The environment and disease: association or causation Proc R Soc Med 1965;58:295-300.
14. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
15. Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-1558.
16. Patsopoulos NA, Evangelou E, Ioannidis JP: Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. Int J Epidemiol 2008;37:1148-1157.
17. Egger M, Davey SG, Schneider M, Minder C: Bias in metaanalysis detected by a simple, graphical test. BMJ 1997;315: 629-634.
18. Begg CB, Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50: 1088-1101.
19. Kantor AF, Hartge P, Hoover RN, Narayana AS, Sullivan JW, Fraumeni JF Jr: Urinary tract infection and risk of bladder cancer. Am J Epidemiol 1984;119:510-515.
20. O'Mara BA, Byers T, Schoenfeld E: Diabetes mellitus and cancer risk: a multisite case-control study. J Chronic Dis 1985;38:435-441.
21. Risch HA, Burch JD, Miller AB, Hill GB, Steele R, Howe GR: Dietary factors and the incidence of cancer of the urinary bladder. Am J Epidemiol 1988;127:1179-1191.
22. La Vecchia C, Negri E, Franceschi S, D'Avanzo B, Boyle P: A case-control study of diabetes mellitus and cancer risk. Br J Cancer 1994;70:950-953.
23. Kravchick S, Gal R, Cytron S, Peled R, Weissman Y, Mukamel E, Koren R: Increased incidence of diabetes mellitus in the patients with transitional cell carcinoma of urinary bladder. Pathol Oncol Res 2001;7:56-59.
24. Ng Y, Husain I, Waterfall N: Diabetes mellitus and bladder cancer-an epidemiological relationship Pathol Oncol Res 2003;9:30-31.
25. Rousseau MC, Parent ME, Pollak MN, Siemiatycki J: Diabetes mellitus and cancer risk in a population-based case-control study among men from Montreal, Canada. Int J Cancer 2006;118:2105-2109.
26. Jiang X, Castelao JE, Groshen S, Cortessis VK, Shibata D, Conti DV, Yuan J-M, Pike MC, Gago-Dominguez M: Urinary tract infections and reduced risk of bladder cancer in Los Angeles. Br J Cancer 2009;100:834-839.
27. MacKenzie T, Zens MS, Ferrara A, Schned A, Karagas MR: Diabetes and risk of bladder cancer: evidence from a case-control study in New England. Cancer 2011;117: 1552-1556.
28. Inoue M, Iwasaki M, Otani T, Sasazuki S, Noda M, Tsuqane S: Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med 2006;166:1871-1877.
29. Rapp K, Schroeder J, Klenk J, Ulmer H, Concin H, Diem G, Oberaigner W, Weiland SK: Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. Diabetologia 2006;49:945-952.
30. Khan M, Mori M, Fujino Y, Shibata A, Sakauchi F, Washino M, Tamakoshi A; Japan Collaborative Cohort Study Group: Site-specific cancer risk due to diabetes mellitus history: evidence from the Japan Collaborative Cohort ( JACC) Study. Asian Pac J Cancer Prev 2006; 7:253-259.
31. Ogunleye AA, Ogston SA, Morris AD, Evans JM: A cohort study of the risk of cancer associated with type 2 diabetes. Br J Cancer 2009;101:1199-1201.
32. Yood MU, Oliveria SA, Campbell UB, Koro CE: Incidence of cancer in a population-based cohort of patients with type 2 diabetes. Diabetes Metab Syndr Clin Res Rev 2009; 3:12-16.
33. Woolcott CG, Maskarinec G, Haiman CA, Henderson BE, Kolonel LN: Diabetes and urothelial cancer risk: the Multiethnic Cohort Study. Cancer Epidemiol 2011;35:551-554.
34. Atchison EA, Gridley G, Carreon JD, Leitzmann MF, McGlynn KA: Risk of cancer in a large cohort of U.S. veterans with diabetes. Int J Cancer 2011;128:635-643.
35. Lo SF, Chang SN, Muo CH, Chen SY, Liao FY, Dee SW, Chen PC, Sung FC: Modest increase in risk of specific types of cancer types in type 2 diabetes mellitus patients. Int J Cancer 2012;132:182-188.
36. Newton CC, Gapstur SM, Campbell PT, Jacobs EJ: Type 2 diabetes mellitus, insulin-use and risk of bladder cancer in a large cohort study. Int J Cancer 2012;132:2186-2191.
37. Prizment AE, Anderson KE, Yuan JM, Folsom AR: Diabetes and risk of bladder cancer among postmenopausal women in the Iowa Women's Health Study. Cancer Causes Control 2013;24:603-608.
38. Lai GY, Park Y, Hartge P, Hollenbeck AR, Freedman ND: The association between self-reported diabetes and cancer incidence in the NIH-AARP Diet and Health Study. J Clin Endocrinol Metab 2013;98:E497-E502.
39. Tripathi A, Folsom AR, Anderson KE: Risk factors for urinary bladder carcinoma in postmenopausal women. The Iowa Women's Health Study. Cancer 2002;95:2316-2323.
40. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ: Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 2004;159:1160-1167.
41. Stocks T, Rapp K, Bjorge T, Manjer J, Ulmer H, Selmer R, Lukanova A, Johansen D, Concin H, Tretli S, Hallmans G, Jonsson H, Stattin P: Blood glucose and risk of incident and fatal cancer in the Metabolic Syndrome and Cancer Project (Me-Can): analysis of six prospective cohorts. PLoS Med 2009;6:e1000201.
42. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R: Diabetes and cancer. Endocr Relat Cancer 2009;16:1103-1123.
43. Vigneri R: Diabetes: diabetes therapy and cancer risk. Nat Rev Endocrinol 2009;5:651-652.
44. Bergenstal RM, Kendall DM, Franz MJ, Rubenstein AH: Management of type 2 diabetes: a systematic approach to meeting the standards of care. II: Oral agents, insulin, and management of complications. In: DeGroot LJ, Jameson JL, eds. Endocrinology, 4th ed. Philadelphia: W.B. Saunders Co., 2001:821-835.
45. Okura Y, Urban LH, Mahoney DW, Jacobsen SJ, Rodeheffer RJ: Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure. J Clin Epidemiol 2004;57:1096-1103.
46. Johnson JA, Carstensen B, Witte D, Bowker SL, Lipscombe L, Renehan AG: Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. Diabetologia 2012;55:1607-1618.
47. Shikata K, Ninomiya T, Kiyohara Y: Diabetes mellitus and cancer risk: review of the epidemiological evidence. Cancer Sci 2013;104:9-14.
48. Tabak AG, Jokela M, Akbaraly TN, Kivimaki M, Witte D: Trajectories of glycemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II Study. Lancet 2009;373:2215-2221.
49. Vella V, Pandini G, Sciacca L, Mineo R, Vigneri R, Pezzino V, Belfiore A: A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. J Clin Endocrinol Metab 2002;87:245-254.
50. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D: Diabetes and cancer: a consensus report. Diabetes Care 2010;33:1674-1685.
51. Currie CJ, Poole CD, Gale EA: The influence of glucoselowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52:1766-1777.
52. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM: New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009;32:1620-1625.
53. Ooi GT, Tseng LY, Tran MQ, Rechler MM: Insulin rapidly decreases insulin-like growth factor-binding protein-1 gene transcription in streptozotocin-diabetic rats. Mol Endocrinol 1992;6:2219-2228.
54. Powell DR, Suwanichkul A, Cubbage ML, DePaolis LA, Snuggs MB, Lee PD: Insulin inhibits transcription of the human gene for insulin-like growth factor-binding protein-1. J Biol Chem 1991;266:18868-18876.
55. Le Roith D: Seminars in medicine of the Beth Israel Deaconess Medical Center: insulin-like growth factors. N Engl J Med 1997;336:633-640.
56. Wolf I, Sadetzki S, Catane R, Karasik A, Kaufman B: Diabetes mellitus and breast cancer. Lancet Oncol 2005;6:103-111.
57. Torrisi R, Mezzetti M, Johansson H, Barreca A, Pigatto F, Robertson C, Decensi A: Time course of fenretinide-induced modulation of circulating insulin-like growth factor (IGF)-I, IGF-II and IGFBP-3 in a bladder cancer chemoprevention trial. Int J Cancer 2000;87:601-605.
58. Zhao H, Grossman HB, Spitz MR, Lerner SP, Zhang K, Wu X: Plasma levels of insulin-like growth factor-1 and binding protein-3, and their association with bladder cancer risk. J Urol 2003;169:714-717.